Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,852 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

NCT00064350
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
141
States / cities
Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT05036135
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101, Placebo
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

NCT00034268
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
LY900003
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
20
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 31, 2026, 1:47 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed No phase listed Observational

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

NCT03921658
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Combating HIV Stigma in Healthcare Settings: A Standardized Patient Approach

NCT06975176
View directory record Official record
Conditions
Hiv
Interventions
Stigma reduction intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated Not applicable Interventional Results available

A Multilevel Intervention in the Hunger Relief Network to Improve Diet Among Adults Experiencing Food Insecurity

NCT03421106
View directory record Official record
Conditions
Food Selection
Interventions
Intervention Food Pantries, Control Food Pantries
Behavioral · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 99 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional

Defeating Urinary Incontinence With Exercise Training (DUET) Feasibility Study

NCT02206958
View directory record Official record
Conditions
Toileting Disability, Functional Urinary Incontinence
Interventions
Defeating Urinary Incontinence with Exercise Training
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
60 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 31, 2026, 1:47 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional Results available

Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)

NCT00289289
View directory record Official record
Conditions
Atrial Fibrillation, Tachycardia, Supraventricular, Arrhythmia, Bradycardia
Interventions
Intervention Pacing Features
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
34
States / cities
Little Rock, Arkansas • Rancho Mirage, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
PF-00734200
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine Interscalene Blocks for Rotator Cuff Repair

NCT03587584
View directory record Official record
Conditions
Acute Pain
Interventions
liposomal bupivacaine, Bupivacaine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

NCT00026338
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
74
States / cities
Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification

NCT03539458
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Insufficiency, Mitral Annular Calcification, Mitral Annulus Calcification, Cardiovascular Diseases, Valve Heart Disease, Heart Valve Diseases, Heart Valve Calcification, Mitral Valve Disease
Interventions
Tendyne Mitral Valve System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Wichita, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Not listed No phase listed Observational

Longitudinal Study of Urea Cycle Disorders

NCT00237315
View directory record Official record
Conditions
Brain Diseases, Metabolic, Inborn, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Interventions
Not listed
Lead sponsor
Andrea Gropman
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Recruiting Not applicable Interventional

Renal Pelvic Denervation Pilot Trial

NCT07005050
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RPD, Active hypertension medical therapy
Device · Drug
Lead sponsor
Verve Medical, Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Surprise, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 4 Interventional

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
103
States / cities
Phoenix, Arizona • Bakersfield, California • Berkeley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 31, 2026, 1:47 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Optimization of Adaptive Rowing Seating

NCT07099625
View directory record Official record
Conditions
Spinal Cord Diseases, Spinal Cord Injuries, Neurodegenerative Disorders, Cerebrovascular Accident With Associated Sequelae
Interventions
Adaptive Indoor Rowing Seat, Paddle Sport adaptive seating system
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

For the Health of Our Children--Clinic Based Treatment of Childhood Obesity

NCT01625910
View directory record Official record
Conditions
Obesity
Interventions
Behavioral counseling
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
4 Years to 8 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

NCT00006760
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, ifosfamide, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
101
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 31, 2026, 1:47 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
LMN-201, Placebo
Drug
Lead sponsor
Lumen Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated Phase 2 Interventional

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

NCT05789524
View directory record Official record
Conditions
Hemophilia a, Hemophilia B
Interventions
SerpinPC
Drug
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

NCT01620255
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, PF-00547659 SC Injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
99
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 1:47 AM EDT